Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy
Jeremy S. Abramson(Harvard University), Andrew M. Evens(Rutgers, The State University of New Jersey), Sonali M. Smith(University of Chicago), Deepa Jagadeesh(University of Massachusetts Chan Medical School), Steven T. Rosen(City of Hope), Tatyana Feldman(Hackensack University Medical Center), Eric S. Winer(Providence College), Aimee Kroll‐Desrosiers(University of Massachusetts Chan Medical School), Jorge J. Castillo(Miriam Hospital), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Christopher R. Flowers(CancerCare Manitoba), André Goy(Rutgers, The State University of New Jersey), Chadi Nabhan(University of Chicago), R. Nath(University of Massachusetts Chan Medical School), Frederick Lansigan(American University of Beirut Medical Center), Bruce A. Woda(University of Massachusetts Chan Medical School), Lori Muffly(Stanford University)
Cited by 138
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
|New England Journal of Medicine|2018|1.1k